Loading organizations...

Insempra: Biomanufacturing company developing sustainable bio-based ingredients using precision fermentation for cosmetics, food, and textiles.
Insempra has raised $51.6M across 4 funding rounds.
Key people at Insempra.
Insempra was founded in 2021 by Jens Klein (CEO & Co-Founder).
Insempra has raised $51.6M in total across 4 funding rounds.
Insempra develops sustainable, high-performance ingredients using precision fermentation and bio-manufacturing to replace petrochemical and agricultural alternatives. The company creates bio-based lipids, polymers, and materials for industries such as cosmetics, food, fragrances, and textiles, focusing on superior properties and reduced environmental impact. Insempra has raised a total of $35 million in funding, including an initial $15 million round in 2021 and a recent $20 million Series A round. Their business model involves building and selling proprietary bio-based specialty ingredients, exemplified by an exclusive global distribution agreement with Brenntag for an omega-7 lipid. Founded in 2021 by Jens Klein and Andreas Heyl, the company recently concluded its $20 million Series A to advance its biomanufacturing platform. Its business model centers on builds and sells proprietary bio-based specialty ingredients, with distribution partnerships like exclusive global agreement with Brenntag.
Insempra was founded in 2021 by Jens Klein (CEO & Co-Founder).
Insempra has raised $51.6M in total across 4 funding rounds.
Insempra's investors include EQT Ventures, 305 Ventures, Alumni Ventures, Atomico, BlueYard Capital, Breakthrough Energy Ventures, Cherry Ventures, DST Global, Iaso Ventures, Philip Chopin, Scott Sandell, Charlie Songhurst.
Key people at Insempra.
Insempra is a biotechnology company that develops sustainable, bio-based ingredients using precision fermentation and bioscience to replace petrochemical-derived materials. It serves brands and original equipment manufacturers (OEMs) in the beauty & personal care, food & nutrition, and fashion industries, addressing the problem of resource depletion and environmental harm from traditional chemical production processes.[1][2][3][4] By growing matter "with nature" at industrial scale, Insempra enables superior, regenerative products that meet consumer demand for sustainability, regulatory pressures, and supply chain predictability, while bridging the gap between R&D labs and market-ready solutions through integrated production facilities.[1][2][3]
The company demonstrates growth momentum through its location at the Innovations- und Gründerzentrum Biotechnologie (IZB) in Germany, where it scales lab operations amid a biotech ecosystem, and backing from investors like Bayern Kapital, positioning it to attract global talent and expand production.[1][3]
Insempra emerged from a founding team with expertise from leading institutions and companies including AMSilk, Clariant, Evonik, Fraunhofer, and Lonza, blending biology, technology, and entrepreneurship to drive a "regenerative revolution."[1][4] The idea crystallized around unleashing nature's potential to grow matter with atomic precision, countering decades of reliance on petrochemicals that deplete resources and pollute the planet—a response to intensifying environmental concerns, consumer demands, and regulations pressuring industries like cosmetics, food, and fashion to adopt sustainable alternatives.[2][3][4]
Early traction includes establishing operations at the IZB biotech hub, which CEO Jens Klein highlighted as ideal for rapid scaling and talent acquisition, and securing portfolio status with Bayern Kapital to fuel industrial-scale fermentation for bio-based ingredients.[1][3]
Insempra rides the wave of the bioeconomy and regenerative biotech trend, where precision fermentation scales lab innovations to replace fossil-fuel-based ingredients amid climate urgency, EU regulatory pushes like the Green Deal, and consumer shifts toward eco-conscious products.[1][2][3] Timing is critical as industries face supply vulnerabilities from petrochemical dependency—Insempra's local, nature-collaborative manufacturing mitigates these, offering predictable sourcing independent of global conflicts.[1]
It influences the ecosystem by partnering with brands to transform formulations, fostering a "new school of thought" in sustainable manufacturing and accelerating the shift from extractive to generative economies, as evidenced by its IZB ecosystem integration and investor support.[1][3][4]
Insempra is poised to expand its technology platform, targeting larger production volumes and deeper partnerships with global brands to dominate bio-based ingredients in high-pressure sectors. Trends like stricter sustainability regulations, advancing fermentation tech, and rising demand for traceable naturals will propel its growth, potentially evolving it into a key enabler of the circular bioeconomy. As biotech hubs like IZB draw talent, expect Insempra to license more innovations and measure success through scaled impact—reinforcing its mission to grow a better future from the ground up.[1][3][4]
Insempra has raised $51.6M across 4 funding rounds. Most recently, it raised $20.0M Series A in May 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 5, 2025 | Solena Materials | $6.7M Seed | — | David Harding, SynBioVen |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $20.0M Series A | EQT Ventures | 305 Ventures, Alumni Ventures, Atomico, BlueYard Capital, Breakthrough Energy Ventures, Cherry Ventures, DST Global, Iaso Ventures, Philip Chopin, Scott Sandell, Charlie Songhurst, Taavet Hinrikus, Acequia Capital, Alante Capital, Bayern Kapital, Henkel Tech Ventures, Possible Ventures |
| Nov 10, 2023 | $1.6M Other Equity | The Federal Agency for Disruptive Innovation | |
| May 26, 2021 | $15.0M Other Equity | EQT Ventures | Charlie Songhurst, Sten Tamkivi, Taavet Hinrikus, Acequia Capital, BlueYard Capital, Inventures |
| May 1, 2021 | $15.0M Seed | EQT Ventures | 305 Ventures, Alumni Ventures, Atomico, BlueYard Capital, Breakthrough Energy Ventures, Cherry Ventures, DST Global, Iaso Ventures, Philip Chopin, Scott Sandell, NFX, Seven Seven Six, Trajectory Ventures, Charlie Songhurst, Justin Mateen, Kevin Weil, Kyle Vogt, Thomas Tull, Trevor Blackwell, Acequia Capital, Inventures, Sten Tamkivi, Taavet Hinrikus |